The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
上岸
Kao
Nole
Criminology34
GingerF
渡人舟
学术文献互助
OK
东方元语
有人
mmyhn
Essence
ming2026
嘻嘻哈哈
吴迪
研研
cdercder
初景
张欢馨
loii
皖公网安备34019202002308
